Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherANALGESIA AND DRUGS OF ABUSE

Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception

Eduardo R. Butelman, Mei-Chuan Ko, Katarzyna Sobczyk-Kojiro, Henry I. Mosberg, Barbara Van Bemmel, Gerald Zernig and James H. Woods
Journal of Pharmacology and Experimental Therapeutics May 1998, 285 (2) 595-601;
Eduardo R. Butelman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mei-Chuan Ko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarzyna Sobczyk-Kojiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry I. Mosberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Van Bemmel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Zernig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James H. Woods
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The binding characteristics of the kappa opioid ligands [3H]U69,593 and [3H]bremazocine, themu opioid ligand [3H][d-ala2,N-Me-Phe4,glycol5]enkephalin and the delta opioid ligand [3H]p-Cl-[d-pen2,5]enkephalin were studied in rhesus monkey brain membranes in saturation binding experiments and were followed by competition binding experiments with a variety of peptidic and nonpeptidic opioid ligands. The [3H]U69,593 sites appeared to be a subset ofkappa opioid receptors (kappa-1 receptors: Kd, 1.2 nM;Bmax, 66 fmol/mg). [3H]Bremazocine (in the presence of mu anddelta receptor-masking agents), bound to a larger population of kappa receptors (kappa-all:Kd, 0.39 nM;Bmax, 227 fmol/mg), which presumably included the aforementioned kappa-1 sites. Competition binding experiments revealed that the presently definedkappa-1 sites were similar to previously reported sites in other mammalian species, particularly in terms of the higherkappa-1 selectivity observed with arylacetamide (e.g., U50,488) vs. benzomorphankappa agonists (e.g., ethylketocyclazocine). The kappa-selective antagonist norbinaltorphimine (nor-BNI) displayed a very small (2.3-fold) selectivity for kappa-1 vs.kappa-all sites. This led to the prediction that in rhesus monkeys (n = 3), systemically administered nor-BNI (10 mg/kg s.c.) should have a very moderate degree of antagonist selectivity for the antinociceptive effects of a putativekappa-1-agonist, the arylacetamide U50,488 (0.1–3.2 mg/kg s.c.), vs. those of the benzomorphankappa agonist ethylketocyclazocine (0.01–056 mg/kg s.c.). This prediction was confirmed in vivo because nor-BNI (10 mg/kg) caused a robust and long lasting (up to 21 days) antagonism of the antinociceptive effects of U50,488 and a small but significant antagonism of ethylketocyclazocine. The arylacetamide congener CI-977 (enadoline), which displayed an 11-foldkappa-1 vs.kappa-all binding selectivity, was not sensitive to nor-BNI pretreatment. This indicates that the kappa subtype-binding profile of an agonist is not necessarily predictive of its sensitivity to nor-BNIin vivo. Overall, the present results suggest that at least two functional kappa receptor populations may be present in rhesus monkey brain.

Footnotes

  • Send reprint requests to: Dr. Eduardo Butelman, Rockefeller University, Box 171, 1230 York Avenue, New York, NY 10021. E-mail:butelme{at}rockvax.rockefeller.edu

  • ↵1 This work was supported by United States Public Health Service Grants DA00254 and DA11113 and a National Institute of Drug Abuse/INVEST Fellowship (G.Z.).

  • ↵2 Present address: Rockefeller University, New York, NY.

  • ↵3 Present address: Department of Neurochemistry, Clinic of Psychiatry, University of Innsbruck, Innsbruck, Austria.

  • Abbreviations:
    CI-977
    enadoline
    DAMGO
    [d-ala2,N-Me-Phe4,glycol5]enkephalin
    s.c.
    subcutaneously
    DPDPE
    [d-pen2,5]enkephalin
    BNI
    binaltorphimine
    MPE
    maximum possible effect
    EKC
    ethylketocyclazocine
    • Received July 22, 1997.
    • Accepted January 20, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 285, Issue 2
1 May 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherANALGESIA AND DRUGS OF ABUSE

Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception

Eduardo R. Butelman, Mei-Chuan Ko, Katarzyna Sobczyk-Kojiro, Henry I. Mosberg, Barbara Van Bemmel, Gerald Zernig and James H. Woods
Journal of Pharmacology and Experimental Therapeutics May 1, 1998, 285 (2) 595-601;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherANALGESIA AND DRUGS OF ABUSE

Kappa-Opioid Receptor Binding Populations in Rhesus Monkey Brain: Relationship to an Assay of Thermal Antinociception

Eduardo R. Butelman, Mei-Chuan Ko, Katarzyna Sobczyk-Kojiro, Henry I. Mosberg, Barbara Van Bemmel, Gerald Zernig and James H. Woods
Journal of Pharmacology and Experimental Therapeutics May 1, 1998, 285 (2) 595-601;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats
  • Delta Opioid Receptor Enhancement ofMu Opioid Receptor-Induced Antinociception in Spinal Cord
  • Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs1
Show more ANALGESIA AND DRUGS OF ABUSE

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics